BLOCK HIV/HCVBringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Knowledge, attitudes, and practices related to hepatitis C among gay and bisexual men in the era of direct-acting antivirals: implications for treatment and prevention.
Brener L, et al. J Cult Health Sex. 2020;22(5):551-567.
Falade-Nwulia O, et al. Int J Drug Policy. 2020;78:102714.
“Everybody living with a chronic disease is entitled to be cured”: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T, et al. Int J Drug Policy. 2020;81:102766.
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis.
Hajarizadeh B, et al. J Hepatol. 2020;72(4):643-657.
Kushner T, Terrault NA. Hepatol Commun. 2019;3(1):20-28.
Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—the practitioner experience.
Marshall AD, et al. Drug Alcohol Depend. 2020;206:107705.
Clients' perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.
Masson CL, et al. BMC Infect Dis. 2020;20(1):386.
Addressing Barriers and Challenges to HCV Elimination
Narrated by Robert Greenwald
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention